Inhibition of RL male 1 tumor growth in BALB/c mice by introduction of the RLakt gene coding for antigen recognized by cytotoxic T-lymphocytes and the GM-CSF gene by in vivo electroporation

Cancer Science

Volumn 95, Issue 2, 2004, Pages 154-159

  Tanaka, Motoyuki ^a   Yamada, Masaharu ^b   Ono, Toshiro ^a   Naguchi, Yuji ^a   Uenaka, Akiko ^a   Ota, Seisuke ^a   Hata, Hidenori ^a   Harada, Mine ^a,c   Tanimoto, Mitsune ^a   Nakayama, Eiichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE; PEPTIDE DERIVATIVE; PLASMID DNA; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; IMMUNIZATION; IN VIVO STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; ELECTROPORATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LEUKEMIA; MALE; MICE; OLIGOPEPTIDES; PLASMIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 12144288305     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03197.x     Document Type: Article

References (45)

1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
2. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356: 152-4.
3. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995; 3: 165-9.
4. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745-9.
5. Raz E, Carson DA. Parker SE, Parr TB, Abai AM, Aichinger G, Gromkowski SH, Singh M, Lew D, Yankauckas MA, et al. Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA 1994; 91: 9519-23.
6. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Immunology, application, and optimization. Annu Rev Immunol 2000; 18: 927-74.
7. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48.
8. Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: A key for inducing long-term cellular immunity. Curr Opin Immunol 2000; 12: 442-7.
9. Mukai K, Yasutomi Y, Watanabe M, Kenjo A, Aota T, Wang L, Nishikawa H, Ishihara M, Fujita T, Kuribayashi K, Shiku H. HER2 peptide-specific CD8(+) T cells are proportionally detectable long after multiple DNA vaccinations. Gene Ther 2002; 9: 879-88.
10. Weiss WR, Ishii KJ, Hedstrom RC, Sedegah M, Ichino M, Barnhart K, Klinman DM, Hoffman SL. A plasmid encoding marine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol 1998; 161: 2325-32.
11. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320-9.
12. Corr M, Tighe H, Lee D, Dudler J, Trieu M, Brinson DC, Carson DA. Costimulation provided by DNA immunization enhances antitumor immunity. J Immunol 1997; 159: 4999-5004.
13. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996; 156: 238-45.
14. Yoshida A, Nagata T, Uchijima M, Higashi T, Koide Y. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine 2000; 18: 1725-9.
15. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, Ulmer JB. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40.
16. Kalat M, Kupcu Z, Schuller S, Zalusky D, Zehetner M, Paster W, Schweighoffer T. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res 2002; 62: 5489-94.
17. Goto T, Nishi T, Tamura T, Dev SB, Takeshima H, Kochi M, Yoshizato K, Kuratsu J, Sakata T, Hofmann GA, Ushio Y. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 2000; 97: 354-9.
18. Mendiratta SK, Thai G, Eslahi NK, Thull NM, Matar M, Bronte V, Pericle F. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp 100 and TRP-2. Cancer Res 2001; 61: 859-63.
19. Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med 1994; 180: 1599-607.
20. Wada H, Matsuo M, Uenaka A, Shimbara N, Shimizu K, Nakayama E. Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: Derivation from the normally untranslated 5′ region of the c-akt proto-oncogene activated by long terminal repeat. Cancer Res 1995; 55: 4780-3.
21. Nakayama E, Shiku H, Takahashi T, Oettgen HF, Old LJ. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1979; 76: 3486-90.
22. Wolfel T, Van Pel A, De Plaen E, Lurquin C, Maryanski JL, Boon T. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum-antigen with a cytolytic T cell stimulation assay. Immunogenetics 1987; 26: 178-87.
23. Dunn T, Potter M. A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst 1957; 18: 587-601.
24. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintans J, Loken MR, Pierres M, Fitch FW. Characterization of the marine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol 1983; 131: 2445-51.
25. Ozato K, Hansen TH, Sachs DH. Monoclonal antibodies to mouse MHC antigens. II. Antibodies to the H-2Ld antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J Immunol 1980; 125: 2473-7.
26. Havell EA. Purification and further characterization of an anti-murine interferon-gamma monoclonal neutralizing antibody. J Interferon Res 1986; 6: 489-97.
27. Tam JP. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988; 85: 5409-13.
28. Saeki Y, Wataya-Kaneda M, Tanaka K, Kaneda Y. Sustained transgene expression in vitro and in vivo using an Epstein-Barr virus replicon vector system combined with HVJ liposomes. Gene Ther 1998; 5: 1031-7.
29. Czerkinsky C, Andersson G, Ekre HP, Nilsson LA, Klareskog L, Ouchterlony O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 1988; 110: 29-36.
30. Manki A, Ono T, Uenaka A, Seino Y, Nakayama E. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Res 1998; 58: 1960-4.
31. Ota S, Ono T, Morita A, Uenaka A, Harada M, Nakayama E. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells. Cancer Res 2002; 62: 1471-6.
32. Wang R, Doolan DL, Le TP, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, Hobart P, Margalith M, Ng J, Weiss WR, Sedegah M, et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476-80.
33. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001; 61: 3698-703.
34. Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN, Nikolic-Zugic J. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188: 1553-61.
35. Schreurs MW, Eggert AA, de Boer AJ, Vissers JL, van Hall T, Offringa R, Figdor CG, Adema GJ. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Cancer Res 2000; 60: 6995-7001.
36. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, Surman DR, Restifo NP, Zanovello P. Genetic vaccination with "sElf" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 2000; 60: 253-8.
37. Harty JT, Bevan MJ. CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J Exp Med 1992; 175: 1531-8.
38. Blake N, Haigh T, Shaka'a G, Croom-Carter D, Rickinson A. The importance of exogenous antigen in priming the human CD8+ T cell response: Lessons from the EBV nuclear antigen EBNA1. J Immunol 2000; 165: 7078-87.
39. Rakhmilevich AL, Imboden M, Hao Z, Macklin MD, Roberts T, Wright KM, Albertini MR, Yang NS, Sondel PM. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 2001; 7: 952-61.
40. Xiang Z, Ertl HC. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995; 2: 129-35.
41. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, Davies ME, Shiver JW, et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 2002; 168: 562-8.
42. Kusakabe K, Xin KQ, Katoh H, Sumino K, Hagiwara E, Kawamoto S, Okuda K, Miyagi Y, Aoki I, Nishioka K, Klinman D. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine. J Immunol 2000; 164: 3102-11.
43. Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S, Hoffman SL, Weiss WR. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000; 165: 3772-81.
44. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-56.
45. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 1995; 92: 2219-23.